https://www.dailymail.co.uk/news/article-9437191/C

New Post Public Reply Private Reply Replies (1) Message Board
Crunch55
575
https://www.dailymail.co.uk/news/article-9437...tests.html

Californian firm 'is getting £2.8BILLION to supply UK lateral flow Covid tests ahead of plan to offer kits to EVERYONE twice-a-week
Innova Medical Group has secured contracts to supply up to a billion Covid tests
It is owned by Pasaca Capital Inc, chaired by Chinese millionaire Charles Huang
The company has its 'primary' factory for making tests in Xiamen city, China
Ministers are hoping to start receiving British-made swabs next month
But they are still waiting for regulators to approve these tests for use in the UK
By LUKE ANDREWS HEALTH REPORTER FOR MAILONLINE

PUBLISHED: 13:29 EDT, 5 April 2021 | UPDATED: 13:29 EDT, 5 April 2021

e-mail
294
shares
View comments
A Californian firm backed by private equity has won deals with No10 to supply more than a billion coronavirus tests ahead of the mass twice-a-week testing drive.

Innova Medical Group has raked in £2.8billion from British taxpayers in controversial deals for lateral flow tests that give results within 30 minutes.

It was officially founded last March by Pasaca Capital, chaired by Chinese businessman Charles Huang who was born in Wuhan - the city at the epicentre of the pandemic.


Innova's 'primary' factory for making coronavirus swabs is in Xiamen in Fujian. It also has three production facilities in the US, and is planning to expand to the UK.

The pharmaceutical's swabs will inevitably used as part of Boris Johnson's pledge to offer every adult in Britain two tests a week from Friday.

But ministers are also hoping to start receiving swabs from UK companies - Omega Diagnostics and Global Access Diagnostics - as soon as their kits get the green light from the medical regulator. They will only be able to supply four million tests a week by the end of next month, compared to Innova's 15million a day.

Scientists held up lateral flow tests as a way out of the pandemic because they could spot asymptomatic cases, helping to limit the spread of the virus.

But some experts have raised concerns that thousands could be wrongly labelled as having Covid by getting 'false positives' because studies have shown the kits are less accurate than gold-standard PCR swabs.

The Government has been accused of 'cronyism' in the way it handed out contracts at the start of the pandemic, amid a desperate scramble for PPE. But ministers insist they have nothing to hide and were working hard to get the necessary equipment to the country in record time.

Innova Medical Group is owned by private equity firm Pasaca Capital Inc, that was set up by Chinese millionaire from Wuhan Charles Huang (pictured). The British taxpayer has already paid £2.8billion to Innova for lateral flow tests +2
Innova Medical Group is owned by private equity firm Pasaca Capital Inc, that was set up by Chinese millionaire from Wuhan Charles Huang (pictured). The British taxpayer has already paid £2.8billion to Innova for lateral flow tests

Boris Johnson is planning to get every adult in the UK to test themselves for the virus twice a week, as more parts of society begin to open up +2
Boris Johnson is planning to get every adult in the UK to test themselves for the virus twice a week, as more parts of society begin to open up

SCIENTISTS URGE GOVERNMENT TO STOP USING INNOVA TEST
Scientists have accused the Government of misleading the public over the accuracy of Innova's rapid test and called for its use to be stopped.

Professor Jon Deeks, Dr Angela Raffle and Dr Mike Gill – from the University of Birmingham, the University of Bristol and a former regional director of public health, respectively – said in a letter published in January: 'The Innova lateral flow test is not fit for many of the purposes being proposed by the government.

'In the Liverpool pilot, the test missed infection in 60 per cent of people, and of greatest concern missed it in 30 per cent of those with very high viral loads who are at highest risk of spreading the virus to others.

'An erroneous test result may lead to people taking the wrong actions and putting themselves and others at risk of infection. This may increase and not reduce disease spread, illness and death.'

They said the limitations of the test were not being made clear by the Department of Health and that it was being made out to be more accurate than it is, in some places being compared to the significantly more reliable PCR tests.

Lateral flow tests do have some benefits, they argued, but the way this was being used risked too many people getting false negative results or not reporting results when they were positive.

The researchers urged in their letter: 'Stop further rollout of rapid asymptomatic testing using the Innova LFD, including its use in care homes, schools, communities and self-testing by untrained people at home.'

A similar, but not identical comment, is available on the British Medical Journal blog.


Innova supplied as many as 500million lateral flow tests to Britain last year for £2billion - or £4 a test, according to the company's website.

Government contracts show it was paid another £800million this year to secure an undisclosed number of tests.

In an interview with the Sunday Times last month, Innova's chief executive Daniel Elliot said the firm was expecting to have supplied a billion tests to Britain, their biggest customer, by mid-April.

'The way to put it, in terms of scale, is we ship a Boeing 777 cargo jet every single day to the UK,' the chief executive told the Guardian last month.

He added UK authorities were 'very surprised' when they found out quite how many swabbing kits the company could supply.

'I think that was the "Aha!" moment for them, because they were tasked with what felt like an impossible task,' he said.

'We had multiple calls within a 24-hour period. They kept asking, "can you really do this?"'

Innova's route to winning multi-million pound deals to supply Britain with Covid tests came through a Northamptonshire businessman, the Mail revealed last November.

Kim Thonger, 61, of Wellingborough, is the UK distributor of Innova's tests, along with his 52-year-old co-director Charles Palmer, who he took on last summer.

Mr Thonger, who has no previous healthcare background and once worked for DKNY shoes and Dr Marten's, agreed to help Mr Elliott negotiate the bureaucracy and trials it had to go through to win its Government deal, it was claimed.

Both he and Mr Palmer get 'a few pence' for every test sold.

The Innova lateral flow test was approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA) following examination at labs in Porton Down.

It was found to be only 79 per cent accurate at rooting out positive cases on average when the test was given by lab scientists.

This dropped to 73 per cent accurate when used by doctors and nurses, and barely 60 per cent accurate when people tested themselves.

Innova did not dispute these results, but said appropriate training in how to administer the tests improved their performance.

The SD Biosensor and Healgen Covid tests have also been approved for use in the UK, although the companies are not yet supplying swabs for the mass testing regime.

The Prime Minister and Health Secretary announced a huge expansion in testing today with free rapid kits made available to everyone in England from this Friday.

But concerns were immediately raised as when used on that scale the tests could wrongly label tens of thousands of people a week as having Covid.

Tories also pointed out that vaccines have been billed as the key to returning to normal, saying it was another example of ministers 'moving the goalposts'.

Allyson Pollock, professor of public health at Newcastle University, told the BBC that mass testing was a 'scandalous waste of money'.

'When the prevalence rate of coronavirus falls as low as it is at the moment then an increasing proportion of cases are likely to be false positives meaning that cases and contacts will self isolate unnecessarily.'

Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 8

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 12

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 9

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 6

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 12

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing $1000 in Lockheed Martin: A Decade of Growth

Updated Category News Views 91

Unlocking the Power of $1000: The Journey of Lockheed Martin Lockheed Martin has excelled in the stock market, delivering impressive returns for investors who bought shares a decade ago. With a current market capitalization of $138.10 billion, this defense powerhouse has consistently outperformed the market, achieving an annualized growth rate that surpasses expectations....

Continue Reading
Fortis Financial Performance Update: Q4 Earnings Insights

Updated Category News Views 169

Fortis Financial Performance Overview Fortis (NYSE: FTS) has recently shared its Q4 earnings results, revealing strong performance that is worth a closer look. The company's earnings announcement not only highlights its financial health but also offers insights for investors and stakeholders alike. Earnings Highlights In its latest announcement, Fortis exceeded earnings...

Continue Reading
Flowers Foods Increases Quarterly Dividend to $0.24 Per Share

Updated Category News Views 100

Flowers Foods Declares Increased Quarterly Dividend Flowers Foods, Inc. (NYSE: FLO) has recently taken significant steps in its financial directives by announcing a quarterly dividend of $0.24 per share. This marks a commendable increase of 4.3% compared to the same quarter last year. Impressively, this is the 90th consecutive quarterly dividend paid by the company....

Continue Reading
Freeport McMoRan Adjusts Copper Sales Amid Production Setbacks

Updated Category News Views 65

Freeport McMoRan to Delay Indonesian Copper Sales Freeport McMoRan, a significant player in the copper mining industry, has announced a postponement of its refined copper sales from Indonesia to the second quarter of 2025. This decision follows a fire incident at its new smelter, causing an unexpected delay in production. Production Challenges at Manyar Smelter The Manyar...

Continue Reading
Snowflake and Palantir: Revolutionizing AI in Data Management

Updated Category News Views 240

Understanding the Important Deal Between Snowflake and Palantir Snowflake Inc. (NYSE: SNOW) has recently entered a significant partnership with Palantir Technologies Inc. (NYSE: PLTR), marking an important milestone in its ambitious journey towards enhancing artificial intelligence (AI) capabilities for businesses. This collaboration aims to foster enterprise AI...

Continue Reading